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attenuated after adjusting for confounders (REM – 1.50, 1.38 and
1.27).
Conclusion: We confirmed poorer BCRS in older women in our
region. This was partially explained by known prognostic factors.
Further research is needed to determine whether biological differ-
ences or sub-optimal management can explain the residual
excess mortality.
doi:10.1016/j.ejcsup.2010.06.042
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Introduction: Biology of breast cancer appears to change with
age. Most studies are small/from multiple centres limiting their
importance.
Methods: From 1973 to 2009, 2000+ EPCs were managed in
Nottingham. Oestrogen receptor (ER) was assessed by immuno-
histochemistry (giving an H-score) on core biopsy for all
patients. A total of 831 patients had primary surgery and 575
had good quality tumour samples available for tissue micro-
array analysis.
Results: Comparing these 831 patients with a younger (<70
years) series (N = 1809), expression of ER (p < 0.001), p53, HER4,
CK14, bcl2 (p < 0.000) and CK 17 (p < 0.05) was found to increase
with age, while reverse was seen with CK 7/8 (p < 0.002), ki67
and E-Cadherin (p < 0.000). No change was observed in PR, HER2,
CK5/6, CK19 and MUC1 expression.
At 66-month median follow-up, for those who did not receive
adjuvant systemic therapy (N = 306), tumour size (p < 0.042), grade
(p < 0.046), axillary stage (p < 0.000) and PR (p < 0.017) were found
to be independent prognostic factors.
At 49-month median follow-up, for patients with ER+ (H-
scoreP 50) tumours, those with H-scoreP 250 had equivalent
5-year breast cancer specific survival (BCSS) regardless of primary
treatment (surgery vs primary endocrine therapy (PET) 95% ver-
sus 93%, p = 0.715). For patients on PET, all those with H-
scoreP 250 achieved clinical benefit as compared to 11 patients
with H-score < 250 who progressed, at 6 months (p < 0.03), the for-
mer also had better BCSS (p < 0.01).
Conclusion: The pattern suggests a less aggressive tumour phe-
notype with advancing age. The ER H-score appears as an excel-
lent surrogate for clinical outcome for ER+ EPCs. It is available
at diagnosis and has a great value in guiding discussion of thera-
peutic options.
doi:10.1016/j.ejcsup.2010.06.043
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Introduction: MiRNAs exert their regulatory effect on gene
expression by binding to the 30 untranslated region (UTR) of target
mRNAs. The let-7 miRNA family are global genetic regulators crit-
ically important for controlling oncogene expression (e.g. KRAS).
Dysregulated let-7 expression is associated with many malignan-
cies including breast cancer, and it is hypothesized that defective
interaction between let-7 and its target KRAS underpins this asso-
ciation and oncogenesis. We hypothesized that a single nucleo-
tide polymorphism (SNP) in the let-7-binding site in KRAS
disrupts let-7 regulation of the oncogene and thus predisposes
to breast cancer.
Methods: A population analysis of the association of the KRAS
variant and breast cancer was performed on a cohort of 1010
breast cancer patients and 1497 age-matched healthy controls.
Genomic DNA isolated from all participants was amplified using
PCR assays designed specifically to identify the T (wild type) or
G (variant) allele. Genotyping results were correlated with
patients’ clinicopathological parameters.
Results: The KRAS variant was present in 15% of all breast can-
cer patients, compared with baseline prevalence of <7%. In partic-
ular the KRAS-variant predicted a significantly increased risk of
developing triple negative breast cancer in premenopausal
women (OR = 4.78, CI = 1.71–13.38, p = 0.015), and patients with
the variant allele were significantly more likely to present with
advanced stage disease (p = 0.03).
Conclusion: These seminal findings suggest that the KRAS-var-
iant acts as a genetic marker of risk for developing triple negative
breast cancer. Predicting risk for this subtype is critically impor-
tant, to permit early screening and intervention for ‘at-risk’
individuals.
doi:10.1016/j.ejcsup.2010.06.044
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Background: Genome-wide association studies, together with
analyses of specific candidate polymorphisms, have identified a
number of low-penetrance breast cancer susceptibility loci. Infor-
mation is scarce about the combined effects on breast cancer
incidence of these genetic variants and of environmental factors
(reproductive, behavioural, and anthropometric risk factors for
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